Abstract |
Deanol and placebo were administered to 10 parkinsonian patients with levodopa-induced dyskinesias in a double-blind, crossover fashion. Deanol and placebo did not differ significantly in their effects on dyskinesias. The reported properties of deanol seem to be attributable to a placebo effect. There was no correlation with the results of the physostigmine test. Despite these disappointing results deanol remains intriguing, because in individual cases remarkable improvements on dyskinesias are reported.
|
Authors | S F Lindeboom, J P Lakke |
Journal | Acta neurologica Scandinavica
(Acta Neurol Scand)
Vol. 58
Issue 2
Pg. 134-8
(Aug 1978)
ISSN: 0001-6314 [Print] Denmark |
PMID | 360761
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Ethanolamines
- Placebos
- Deanol
- Levodopa
- Physostigmine
|
Topics |
- Aged
- Clinical Trials as Topic
- Deanol
(therapeutic use)
- Double-Blind Method
- Drug Evaluation
- Dyskinesia, Drug-Induced
(drug therapy)
- Ethanolamines
(therapeutic use)
- Female
- Humans
- Levodopa
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Parkinson Disease
(drug therapy)
- Physostigmine
(therapeutic use)
- Placebos
|